← Back to Search

Non-invasive Brain Stimulation

Transcranial Magnetic Stimulation for Depression

N/A
Recruiting
Research Sponsored by Florida State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 15 minutes post-intervention
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether iTBS can improve symptoms in people with depression by targeting the brain's reward circuit.

Who is the study for?
This trial is for right-handed, English-speaking individuals who experience a lack of pleasure or interest in activities (anhedonia). They must not have metal implants in their head, brain conditions like tumors or multiple sclerosis, substance abuse issues within the last three months, severe mental health disorders that affect safety during the trial, high suicide risk, OCD, or be taking certain medications.
What is being tested?
The study is testing intermittent theta-burst transcranial magnetic stimulation (iTBS), which is a non-invasive procedure targeting the brain's reward circuit to see if it can improve feelings of pleasure and motivation.
What are the potential side effects?
While iTBS is generally considered safe, potential side effects may include discomfort at the stimulation site on the scalp, headache, lightheadedness or dizziness. Rarely it could cause seizures but this is uncommon.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 week post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 week post-intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Anhedonia post-intervention
Change in Anhedonia post-washout
Change in RewP post-intervention measured via EEG
+1 more
Secondary study objectives
Change in Reward activation measured via fMRI
Change in Reward connectivity measured via fMRI

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MPFC-iTBSExperimental Treatment1 Intervention
Transcranial magnetic stimulation delivered to the medial prefrontal cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
Group II: Inion-iTBSActive Control1 Intervention
Transcranial magnetic stimulation delivered to the inion. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
transcranial magnetic stimulation
2013
Completed Phase 2
~760

Find a Location

Who is running the clinical trial?

Florida State UniversityLead Sponsor
220 Previous Clinical Trials
36,395 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,918 Previous Clinical Trials
2,739,894 Total Patients Enrolled

Media Library

Intermittent Theta-Burst Transcranial Magnetic Stimulation (iTBS) (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05468853 — N/A
Transcranial Magnetic Stimulation Research Study Groups: MPFC-iTBS, Inion-iTBS
Transcranial Magnetic Stimulation Clinical Trial 2023: Intermittent Theta-Burst Transcranial Magnetic Stimulation (iTBS) Highlights & Side Effects. Trial Name: NCT05468853 — N/A
Intermittent Theta-Burst Transcranial Magnetic Stimulation (iTBS) (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05468853 — N/A
~18 spots leftby Nov 2025